Maintaining an Adult Hematology/Oncology Service at a Tertiary Care Center during the SARS-CoV-2 Pandemic: An Eight-Week-Experience with a Newly Implemented Procedural Plan.
COVID-19
Pandemic
Procedural plan
SARS-CoV-2
Journal
Oncology research and treatment
ISSN: 2296-5262
Titre abrégé: Oncol Res Treat
Pays: Switzerland
ID NLM: 101627692
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
07
2020
accepted:
12
03
2021
pubmed:
4
5
2021
medline:
8
6
2021
entrez:
3
5
2021
Statut:
ppublish
Résumé
Treatment of cancer patients has become challenging when large parts of hospital services need to be shut down as a consequence of a local COVID-19 outbreak that requires rapid containment measures, in conjunction with the shifting of priorities to vital services. Reports providing conceptual frameworks and first experiences on how to maintain a clinical hematology/oncology service during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are scarce. Here, we report our first 8 weeks of experience after implementing a procedural plan at a hematology/oncology unit with its associated cancer center at a large academic teaching hospital in Germany. By strictly separating team workflows and implementing vigorous testing for SARS-CoV-2 infections for all patients and staff members irrespective of clinical symptoms, we were successful in maintaining a comprehensive hematology/oncology service to allow for the continuation of treatment for our patients. Notably, this was achieved without introducing or further transmitting SARS-CoV-2 infections within the unit and the entire center. Although challenging, our approach appears safe and feasible and may help others to set up or optimize their procedures for cancer treatment or for other exceedingly vulnerable patient cohorts.
Identifiants
pubmed: 33940575
pii: 000515828
doi: 10.1159/000515828
pmc: PMC8247812
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
354-359Informations de copyright
© 2021 S. Karger AG, Basel.
Références
Lancet Haematol. 2020 May;7(5):e365-e366
pubmed: 32246913
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Clin Med. 2020 Feb 17;9(2):
pubmed: 32079150
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Ann Hematol. 2021 Feb;100(2):383-393
pubmed: 33159569
J Clin Med. 2020 Feb 04;9(2):
pubmed: 32033064
Oncol Res Treat. 2020;43(6):307-313
pubmed: 32380501
Leukemia. 2020 Jun;34(6):1487-1494
pubmed: 32358568
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Haematol. 2020 May;7(5):e359-e362
pubmed: 32246912
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Lancet Oncol. 2009 Jun;10(6):589-97
pubmed: 19482247
Ann Oncol. 2020 May;31(5):553-555
pubmed: 32201224